At a Glance
- Company: Sidewinder Therapeutics
- Investor lead: OrbiMed
- Deal value: $137 million Series B
- Focus area: Antibody-drug conjugate programmes in oncology
- Next steps: Advance lead ADC candidates toward IND filing and clinical trials
What happened?
Sidewinder Therapeutics, an antibody-drug conjugate focused biotech backed by OrbiMed, closed a $137 million Series B financing round. The capital will be used to advance Sidewinder’s pipeline of differentiated ADC programmes targeting solid tumours and haematological malignancies, continuing the company’s build-out since its Series A launch.
Why does it matter?
The ADC field has seen a wave of billion-dollar deals and acquisitions — including Gilead’s Tubulis buy and a string of big pharma partnerships — driven by clinical successes like Enhertu and Trodelvy. Sidewinder’s ability to close a $137 million round at Series B stage reflects sustained institutional conviction that next-generation conjugation chemistries, novel linkers and differentiated payloads can yield improved therapeutic indices over first-wave ADCs, particularly in solid tumour histotypes that remain hard to treat.
Who’s behind it?
OrbiMed, one of the world’s largest dedicated healthcare investment firms, led the round and has been a consistent backer of Sidewinder since inception. The broader syndicate reflects crossover and specialist biotech investor interest in the ADC space, where clinical validation has made it easier to attract growth-stage capital for pre-IND and early clinical platforms.
How was it achieved?
Sidewinder has been building its ADC platform around differentiated payload and linker combinations designed to improve tumour penetration, bystander killing and tolerability versus approved benchmark agents. The Series B proceeds allow the company to accelerate multiple programmes in parallel, reducing concentration risk and increasing the probability of clinical proof-of-concept across different target and tumour settings.
What’s next?
Sidewinder will use the financing to progress lead programmes toward IND-enabling studies and first-in-human trials, with the goal of generating early clinical data that could support partnerships with larger oncology-focused pharma companies. Given the competitive deal environment for validated ADC assets — evidenced by Merck, AstraZeneca, BMS and Pfizer all actively seeking to in-license — Sidewinder is well positioned to attract partnership interest once clinical signals emerge.